Kyle M. Kampman
Professor of Psychiatry at the Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia
Staff Physician, Veterans Affairs Medical Center, Philadelphia PA
Department: Psychiatry
Contact information
University of Pennsylvania
Center for Studies of Addiction
3535 market Street
Philadelphia, PA 19104
Center for Studies of Addiction
3535 market Street
Philadelphia, PA 19104
Office: 215 746 2764
Fax: 1215 746 2764
Fax: 1215 746 2764
Education
B.A. (Chemistry)
Northwestern University, 1981.
MD
Tulane University, 1985.
B.A. (Chemistry)
Northwestern University, 1981.
MD
Tulane University, 1985.
Post-Graduate Training
Intern in Medicine, Naval Hospital, Bethesda, 1985-1986.
Assistant Instructor in Psychiatry, Hospital of the University of Pennsylvania, Philadelphia, 1990-1993.
Fellowship, Addiction Psychiatry, University of Pennsylvania Treatment Research Center, Philadelphia, 1993-1994.
Permanent linkIntern in Medicine, Naval Hospital, Bethesda, 1985-1986.
Assistant Instructor in Psychiatry, Hospital of the University of Pennsylvania, Philadelphia, 1990-1993.
Fellowship, Addiction Psychiatry, University of Pennsylvania Treatment Research Center, Philadelphia, 1993-1994.
Selected Publications
Vickers-Smith R, Crist RC, Kember RL, Kampman KM, Justice A; VA Million Veteran Program; Kranzler HR.: Racial and ethnic disparities in buprenorphine retention and treatment outcome in a longitudinal cohort of U.S. veterans with opioid use disorder. Am J Drug Alcohol Abuse 2026.White DM, Kimmel PL, Dember LM, Wilkie C, Edwards DP, Williams J, Bernardo L, Quintana N, Cheatle MD, Lash JP, Fischer MJ, Schmidt R, Doorenbos A, Schrauben S, Johansen KL; HOPE Consortium, a member of the HEAL Initiative.: Patient Engagement in the Design and Conduct of the HOPE Trial: Addressing Chronic Pain in Hemodialysis Patients. Clin J Am Soc Nephrol 20: 1461-1469, Oct 2025.
Dember LM, Hsu JY, Mehrotra R, Cavanaugh KL, Kalim S, Charytan DM, Fischer MJ, Jhamb M, Johansen KL, Becker WC, Pellegrino B, Eneanya ND, Schrauben SJ, Pun PH, Unruh ML, Morasco BJ, Mehta M, Miyawaki N, Penfield J, Bernardo L, Brintz CE, Cheatle MD, Doorenbos AZ, Heapy AA, Keefe FJ, Krebs EE, Kuzla N, Nigwekar SU, Schmidt RJ, Steel JL, Wetmore JB, White DM, Kimmel PL, Cukor D; HOPE Consortium.: Pain Coping Skills Training for Patients Receiving Hemodialysis: The HOPE Consortium Randomized Clinical Trial. JAMA Intern Med 185: 197-207, Feb 2025.
Davis CN, Khan Y, Crist RC, Vickers-Smith R, Hartwell EE, Gelernter J, Kampman K, Kember RL, Le Moigne A, Laffont CM, Kranzler HR.: Multi-ancestry genome-wide association meta-analysis of buprenorphine treatment response. Neuropsychopharmacology 2025.
Kurz M, Guerra-Alejos BC, Min JE, Seaman SR, Piske M, Bach P, Bruneau J, Greenland S, Gustafson P, Kampman K, Karim ME, Korthuis PT, Platt RW, Siebert U, Socías ME, Wood E, Nosyk B.: Comparative effectiveness of urine drug testing schedules alongside opioid agonist treatment: Emulation of a population-based target trial in British Columbia, Canada. Addiction 2025.
Nosyk B, Min JE, Homayra F, Kurz M, Guerra-Alejos BC, Yan R, Piske M, Seaman SR, Bach P, Greenland S, Karim ME, Siebert U, Bruneau J, Gustafson P, Kampman K, Korthuis PT, Loughin T, McCandless LC, Platt RW, Schnepel KT, Socías ME.: Buprenorphine/Naloxone vs Methadone for the Treatment of Opioid Use Disorder. JAMA Oct 2024.
Thakrar AP, Christine PJ, Siaw-Asamoah A, Spadaro A, Faude S, Snider CK, Delgado MK, Lowenstein M, Kampman K, Perrone J, Nelson LS, Kilaru AS.: Buprenorphine-Precipitated Withdrawal Among Hospitalized Patients Using Fentanyl. JAMA Netw Open 7: e2435895, Sep 2024.
Shi Z, Li X, Kampman KM, Childress AR, Wiers CE, Langleben DD.: Depressive Symptomatology Is Associated With Smaller Reductions in Drug Cue Reactivity During Extended-Release Naltrexone Treatment of Opioid Use Disorder. J Clin Psychiatry 84: 22br14567, Apr 2023.
Stewart RE, Cardamone NC, Mandell DS, Kwon N, Kampman KM, Knudsen HK, Tjoa CW, Marcus SC.: Not in my treatment center: Leadership's perception of barriers to MOUD adoption. J Subst Abuse Treat 2023.
Krouse RA, Morales KH, Kampman KM, Chakravorty S.: The role of baseline insomnia in moderating the hypnotic properties of quetiapine. Addict Behav 2023.